Pediatric Gastroenterology, Hepatology & Nutrition
- Volume 11 Issue 1
- /
- Pages.28-35
- /
- 2008
- /
- 2234-8646(pISSN)
- /
- 2234-8840(eISSN)
Infliximab: The Benefit for Refractory Crohn Disease and Top-down Induction Therapy in Severe Crohn Disease
Infliximab: 불응성 크론병 치료법으로서의 유용성과 Top-down 관해 유도 요법으로서의 가능성
- Lee, Jee-Hyun (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
- Lee, Hae-Jeong (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
- Park, Sung-Eun (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
-
Choe, Yon-Ho
(Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
- 이지현 (성균관대학교 의과대학 삼성서울병원 소아청소년과학교실) ;
- 이해정 (성균관대학교 의과대학 삼성서울병원 소아청소년과학교실) ;
- 박성은 (성균관대학교 의과대학 삼성서울병원 소아청소년과학교실) ;
-
최연호
(성균관대학교 의과대학 삼성서울병원 소아청소년과학교실)
- Received : 2008.01.31
- Accepted : 2008.02.29
- Published : 2008.03.30
Abstract
Purpose: The aim of this study is to report the efficacy of infliximab, a monoclonal antibody directed against tumor necrosis factor alpha which is used for both treatment of refractory pediatric Crohn disease (CD) and induction of remission. Methods: Among pediatric patients who were diagnosed with CD at Samsung Medical Center between March 2001 and August 2007, a total of 16 patients were given infliximab to treat conventional therapyresistant refractory CD and severe active CD for induction of remission. Patients needing maintenance therapy were treated with an infliximab infusion every 8 weeks, and fistulizing CD patients occasionally received the infusion upon the condition that a fistula developed. The efficacy of treatment was assessed by comparing the Pediatric Crohn Disease Activity Index (PCDAI), Hct, ESR, CRP, and serum albumin levels using paired t-test. Results: The male/female ratio was 13:3, and the median age was 13 years (range, 21 months~15 years). The patients included 7 cases of therapy-resistant refractory CD, 7 cases of severe active CD, and 2 cases of fistulizing CD. Mean PCDAI before infliximab therapy was 34.19
목 적: 종양 괴사 인자(TNF-